FOR US HEALTHCARE PROFESSIONALS

For the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

AkebiaCares

Your partner in helping patients access the medication they need

“ They are extremely easy to work with. I am very thankful for having that support for my patients and them always being available.”

— Constance Nicastro-Bowman, CNP Nurse Practitioner

AURYXIA is on formulary with the majority of commercial plans1

With the AURYXIA Copay Coupon, eligible patients can pay as little as $0 per fill and may receive*:

For 90 tablets or less

For 90 tablets or less
Up to $500 off prescriptions

For 91-181 tablets

For 91-181 tablets
Up to $1,000 off prescriptions

For 181 tablets or more

For 181 tablets or more
Up to $1,500 off prescriptions

*AURYXIA is supplied as bottles of 200-count 210 mg ferric iron tablets.2 Restrictions may apply. Copay assistance is not valid for prescriptions reimbursed under Medicare, Medicaid, or similar federal or state programs.

Free AURYXIA may be provided to patients1:

  • With no insurance
  • Whose insurance does not cover AURYXIA

FIND SUPPORT OPTIONS


Eligible patients can get AURYXIA for little or no cost*†

REIMBURSEMENT HELP

REIMBURSEMENT HELP

One-on-one support for assistance with insurance questions and challenges

PATIENT ASSISTANCE PROGRAMS (PAP)

PATIENT ASSISTANCE PROGRAMS (PAP)

For patients who are uninsured or have other coverage concerns, AkebiaCares offers comprehensive patient services that may be able to help

COPAY COUPON

COPAY COUPON

Financial assistance for patients with commercial insurance‡

  • Visit AkebiaCaresHCP.com for copay enrollment

*AURYXIA is supplied as bottles of 200-count 210 mg ferric iron tablets.2 Restrictions may apply. Copay assistance is not valid for prescriptions reimbursed under Medicare, Medicaid, or similar federal or state programs.

†Patients with an income of up to 600% Federal Poverty Level (FPL) may be eligible for free AURYXIA. Additional restrictions apply.
AkebiaCares does not guarantee coverage and/or reimbursement for all patients.

‡Copay assistance is not valid for prescriptions reimbursed under Medicare, Medicaid, or similar federal or state programs.

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS
The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

INDICATION

AURYXIA® (ferric citrate) is indicated for:

  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information

REFERENCES

  1. Data on File 24, Akebia Therapeutics, Inc.
  2. Data on File 29, Akebia Therapeutics, Inc.
  3. AURYXIA® [Package Insert]. Cambridge, MA: Akebia Therapeutics, Inc.; 2021.